Comparison between Goldline Pharmaceutical IPO and Mopshop Distribution IPO.
Goldline Pharmaceutical IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Mopshop Distribution IPO is a SME Bookbuilding proposed to list at BSE SME.
| Goldline Pharmaceutical IPO | Mopshop Distribution IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Cumulative Capital Pvt.Ltd. | Khandwala Securities Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Cameo Corporate Services Ltd. |
| Market Maker | Nirman Share Brokers Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Goldline Pharmaceutical IPO is up to ₹11.02 Cr whereas the issue size of the Mopshop Distribution IPO is up to ₹0.00 Cr. The final issue price of Goldline Pharmaceutical IPO is ₹43.00 per share and of Mopshop Distribution IPO is .
| Goldline Pharmaceutical IPO | Mopshop Distribution IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹41.00 per share | |
| Issue Price (Upper) | ₹43.00 per share | |
| Issue Price (Final) | ₹43.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 3000 shares | |
| Fresh Issue Size | 25,62,000 shares | 16,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹11.02 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 3,75,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 25,62,000 shares | 19,75,000 shares |
| Issue Size Total (Amount) | up to ₹11.02 Cr | up to ₹0.00 Cr |
Goldline Pharmaceutical IPO opens on May 12, 2026, while Mopshop Distribution IPO opens on . The closing date of Goldline Pharmaceutical IPO and Mopshop Distribution IPO is May 14, 2026, and , respectively.
| Goldline Pharmaceutical IPO | Mopshop Distribution IPO | |
|---|---|---|
| Anchor Bid Date | May 11, 2026 | |
| Issue Open | May 12, 2026 | |
| Issue Close | May 14, 2026 | |
| Basis Of Allotment (Tentative) | May 15, 2026 | |
| Initiation of Refunds (Tentative) | May 18, 2026 | |
| Credit of Share (Tentative) | May 18, 2026 | |
| Listing date (Tentative) | May 19, 2026 | |
| Anchor Lockin End date 1 | Jun 14, 2026 | |
| Anchor Lockin End date 2 | Aug 13, 2026 |
Goldline Pharmaceutical IPO P/E ratio is 10.47, as compared to Mopshop Distribution IPO P/E ratio of .
| Goldline Pharmaceutical IPO | Mopshop Distribution IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 79.70 | 99.99 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 57.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 10.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹41.28 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 35.83 | 51.56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 38.45 | 59.70 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.50 | 0.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.37 | 51.56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Goldline Pharmaceutical IPO Retail Individual Investors (RII) are offered 9,00,000 shares while in Mopshop Distribution IPO retail investors are offered 9,00,000 shares. Qualified Institutional Buyers (QIB) are offered 5,40,000 shares in Goldline Pharmaceutical IPO and 0 shares in Mopshop Distribution IPO.
| Goldline Pharmaceutical IPO | Mopshop Distribution IPO | |
|---|---|---|
| Anchor Investor Reservation | 7,32,000 shares | 0 shares |
| Market Maker Reservation | 1,38,000 shares | 0 shares |
| QIB | 5,40,000 shares | 0 shares |
| NII | 3,90,000 shares | 0 shares |
| RII | 9,00,000 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 25,62,000 shares | 0 shares |
Goldline Pharmaceutical IPO subscribed 600.53x in total, whereas Mopshop Distribution IPO subscribed .
| Goldline Pharmaceutical IPO | Mopshop Distribution IPO | |
|---|---|---|
| QIB (times) | 180.22x | |
| NII (times) | 1,662.04x | |
| Big NII (times) | 2,010.60x | |
| Small NII (times) | 980.75x | |
| RII (times) | 881.15x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 600.53x |
